**INFORMATION DISCLOSURE STATEMENT**

Applicant : Sircar et al.
App. No : 10/661,139
Filed : September 12, 2003
For : PHENYL-INDOLE COMPOUNDS
FOR MODULATING IgE AND
INHIBITING CELLULAR
PROLIFERATION
Examiner : Shameem, Golam M.
Art Unit : 1626

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 3 references to be considered by the Examiner. Also enclosed are 3 non-patent literature references as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed after the mailing date of a final action or after the mailing date of a Notice of Allowance. This Statement is accompanied by the fee set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

01/22/2007 140217E1 02002053 10061139

01 FC:1686

100.00 JP

Appl. No. : 10/661,139
Filed : September 12, 2003

Docket No. AVANIR.111A
Customer No. 20,995


CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(2)

I hereby certify that no item of information contained in this Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than 3 months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 1/19/07

By: 

Agnes Juang, Ph.D.
Registration No. 55,310
Attorney of Record
Customer No. 20,995
(949) 760-0404

3327667/lhg
011907

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 1

| | |
|----------------------|--------------------|
| Application No. | 10/661,139 |
| Filing Date | September 12, 2003 |
| First Named Inventor | Sircar et al. |
| Art Unit | 1626 |
| Examiner | Shameem, Golam M. |
| Attorney Docket No. | AVANIR.111A |

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. | Document Number Number - Kind Code (if known) Example: 1,234,567 B1 | Publication Date MM-DD-YYYY | Name of Patentee or Applicant | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
|-------------------|----------|---|--------------------------------|-------------------------------|--|
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. | Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1 | Publication Date MM-DD-YYYY | Name of Patentee or Applicant | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | T ¹ |
|-------------------|----------|--|--------------------------------|----------------------------------|--|----------------|
| | | | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ¹ |
|-------------------|----------|---|----------------|
| | | Golub et al., Science, Vol. 286, October 15, 1999, pp. 531-537. | |
| | | Farina, et al., IL Farmaco, 2001, "Novel bone antiresorptive agents tht selectively inhibit the osteoclast V-H+-ATPase", Vol. 56, pp. 113-116. | |
| | | Viscardi et al., Journal of Heterocyclic Chemistry, 1990, "Heterocyclic X-azolopyridine intermediates", Vol. 27, pp. 1825-9. | |
| | | | |
| | | | |

3327696/lfg
011907

Examiner Signature

Date Considered

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.